E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
CMV reactivation after allogeneic stem cell transplantation. |
|
E.1.1.1 | Medical condition in easily understood language |
CMV infection, disease, and related complications occuring in people who's immune system has been affected by a bone marrow transplant for leukaemia, MDS or lymphoma. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 16.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10049107 |
E.1.2 | Term | CMV viraemia |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Part 1 -To assess the adequacy of the primary endpoint, overall mortality, through one year post-transplant to evaluate the vaccine efficacy of ASP0113 in HCT recipients, and, if necessary, select additional components for an alternative primary composite endpoint. -To evaluate the safety of ASP0113 in subjects undergoing allogeneic HCT Part 2 -To evaluate the vaccine efficacy of ASP0113 compared with placebo as measured by overall mortality or an alternative primary composite endpoint selected based on Part 1 results, through one year post-transplant. -To evaluate the safety of ASP0113 in subjects undergoing allogeneic HCT. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
Pharmacogenomics Sub-Study, 27 March 2013 The pharmacogenomic research that will be conducted in the future with acquired saliva samples is exploratory. The objective of this research is to comprehensively analyze: -Suspected disease-related genes. -Genes of relevance to clinical response, pharmacokinetics, and toxicity/safety issues, to be identified in a pecautionary/retrospective setting.
Donor Sub-Study, 27 March 2013 If a subject has consented and is participating in the optional donor cell sub-study, a 1 mL sample of the donor cell product will be obtained to test for CMV-specific T-cells on the day of transplant (donor cell infusion).
Abbott Molecular Sub-Study, 18 March 2013 Abbott RealTime CMV is marketed in Europe and other parts of the world for use in deciding to begin anti-viral treatment along with other symptoms and tests that may be present. It is also used to check how a patient is responding to anti-viral treatment. The objectives of this protocol are: -To provide viral load results for plasma specimens collected from HCT recipients enrolled in Astellas protocol 0113-CL-1004 for routine surveillance of viremia. -To evaluate the investigational Abbott RealTime CMV assay with plasma and whole blood specimens collected from HCT recipients. The results of this study may be included in one or more premarket submissions to regulatory agencies including the US FDA. |
|
E.3 | Principal inclusion criteria |
1. Institutional Review Board (IRB)/Independent Ethics Committee (IEC)-approved written informed consent and privacy language as per national regulations (e.g., HIPAA Authorization for U.S. sites) must be obtained from the subject or legally authorized representative prior to any study-specific related procedures (including withdrawal of prohibited medication, if applicable). 2. Subject is a male or female subject who is at least 18 years old or the legal age of consent (whichever is greater). 3. Subject is a CMV-seropositive HCT recipient as confirmed by local laboratory at Screening. 4. Subject is planned to undergo either of the following: a. Sibling Donor Transplant - 7/8 HLA-A, -B, -C, -DRß1 match utilizing high resolution typing or 8/8 HLA-A, -B, -C, -DRß1 match utilizing low or high resolution typing. b. Unrelated Donor Transplant - 7/8 or 8/8 HLA-A, -B, -C, -DRß1 match utilizing high resolution typing. 5. Subject is scheduled to receive an allogeneic peripheral blood stem cell (PBSC) or bone marrow transplant (BMT) for the treatment of hematologic disorders as indicated in Inclusion Criterion 6. 6. Subject has one of the following underlying diseases a. Acute myeloid leukemia (AML), with or without a history of myelodysplastic syndrome, in first or second complete remission or in early relapse (< 20% blasts in bone marrow with no circulating blasts in peripheral blood and no extramedullary leukemia). b. Acute lymphoblastic leukemia (ALL), in first or second complete remission. c. Acute undifferentiated leukemia (AUL) in first or second complete remission. d. Acute biphenotypic leukemia in first or second complete remission. e. Chronic myelogenous leukemia (CML) in either chronic or accelerated phase. f. Chronic lymphocytic leukemia (CLL). g. One of the following myelodysplastic syndrome(s) (MDS) defined by the following: i. Refractory anemia. ii. Refractory anemia with ringed sideroblasts. iii. Refractory cytopenia with multilineage dysplasia. iv. Refractory cytopenia with multilineage dysplasia and ringed sideroblasts. v. Refractory anemia with excess blasts-1 (5-10% blasts). vi. Refractory anemia with excess blasts-2 (10-20% blasts). vii. Myelodysplastic syndrome (MDS), unclassified. viii. MDS associated with isolated del (5q). ix. Chronic myelomonocytic leukemia (CMML). h. Primary or secondary myelofibrosis without leukemic transformation except if Dynamic International Prognostic Scoring System (DIPSS) category of high or intermediate-2. i. Lymphoma (including Hodgkin?s) with chemosensitive disease (> 50% response to chemotherapy). |
|
E.4 | Principal exclusion criteria |
1. Subject has active CMV disease or infection or has received treatment for active CMV disease or infection within 3 months (90 days) prior to transplant. 2. Subject has planned CMV prophylactic therapy with antiviral drugs or CMV-specific immunoglobulins from Randomization through the Primary Study Period Completion/Day 365 Visit (Visit 14). 3. Subject has a modified hematopoietic cell transplant comorbidity index (HCT-CI) score > 3. 4. Subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C RNA. 5. Donor CMV serostatus is unknown. 6. Subject has received any of the following substances or treatments: a. Alemtuzumab within 60 days prior to transplant, including conditioning regimen. Subjects for whom treatment with alemtuzumab is planned at any time from 60 days prior to through one year post-transplant should not be enrolled in the trial. b. T cell depletion of donor cell product. c. Administration of a CMV vaccine, including any prior exposure to ASP0113. 7. Subject has received an allogeneic stem cell transplant within one year prior to transplant (subjects who have received a prior autologous transplant are allowed). 8. Subject has a current malignancy in addition to the malignancy being treated for the study or the subject has a history of any other malignancy (within the past 5 years prior to Screening) except non-metastatic basal or squamous cell carcinoma of the skin that has been treated successfully or cancer in situ of the cervix uteri that has been handled by local surgery. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary variable for Part 1 is overall mortality through one year post-transplant. For Part 2, the primary endpoint may be the same or may be changed to a composite endpoint with additional components from the following CMV EOD, aGVHD, cGVHD, and serious bacterial, viral, or fungal infections selected based on the results of Part 1 and a pre-specified algorithm. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Through one year post-transplant. |
|
E.5.2 | Secondary end point(s) |
-Time to first protocol-defined CMV viremia load [CMV plasma viral > 1560 IU/mL (1000 copies/mL by the Abbott RealTime CMV assay) as assessed by the central laboratory] through one year post-transplant. -Time to first adjudicated CMV-specific AVT through one year post ?transplant. -Time to first CMV-specific AVT for protocol-defined CMV viremia [CMV plasma viral load > 1560 IU/mL (1000 copies/mL by the Abbott RealTime CMV assay) as assessed by the central laboratory] or CMV EOD through one year post-transplant. -Incidence of severe treatment-emergent infections other than CMV through one year post-transplant. -Time to severe treatment-emergent infections other than CMV through one year post-transplant. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Through one year post-transplant. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | Yes |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 12 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 35 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Canada |
France |
Germany |
Japan |
Korea, Democratic People's Republic of |
Spain |
Sweden |
Taiwan |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
For regulatory reporting purposes, the end of the trial will be the last visit of the last subject during the primary study period (day 365/Visit 14). An addendum to the clinical study report will be prepared after completion of the long-term follow up period (5.5 years post transplant). |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 7 |
E.8.9.1 | In the Member State concerned months | 9 |
E.8.9.1 | In the Member State concerned days | 30 |
E.8.9.2 | In all countries concerned by the trial years | 7 |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 30 |